| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
microtubule
Myoseverin targets the microtubule cytoskeleton. However, unlike classic microtubule drugs like colchicine or taxol, myoseverin does not appear to bind to tubulin directly. Its exact molecular target is not fully elucidated, but it is known to disrupt microtubule dynamics and induce the fission of multinucleated myotubes. This effect is specific and reversible, making it a unique tool for studying cytoskeletal dynamics. |
|---|---|
| ln Vitro |
In vitro, myoseverin is primarily known for its ability to induce the fission of multinucleated myotubes (skeletal muscle cells) into individual mononucleated cells. This process is reversible upon removal of the compound. The compound's effect is specific to myotubes and does not affect other cell types in the same way. It has also been shown to affect microtubule dynamics in other cell types, but its most striking phenotype is myotube fission.
|
| ln Vivo |
In vivo data for myoseverin are limited. Its potential for tissue engineering and regenerative medicine has been explored, but its in vivo efficacy is not well-characterized. Its ability to generate mononucleated cells from myotubes suggests it could be used to generate cells for transplantation. Further studies are needed to evaluate its potential in vivo.
|
| Enzyme Assay |
In vitro assays for myoseverin typically involve the culture of myoblasts that are allowed to differentiate into multinucleated myotubes. The compound is added to the culture medium, and the cells are observed for the fission of myotubes into mononucleated cells. The effect can be quantified by counting the number of nuclei per cell or by measuring the release of creatine kinase. The reversibility of the effect is tested by removing the compound.
|
| Cell Assay |
For cell-based assays, myoblasts (e.g., C2C12 cells) are cultured in standard media and differentiated into myotubes. The myotubes are then treated with myoseverin at various concentrations. The degree of myotube fission is assessed by microscopy after staining the cells to visualize nuclei and the actin cytoskeleton. The effects on cell viability are measured using standard assays. All experiments include appropriate vehicle controls.
|
| Animal Protocol |
In vivo studies with myoseverin would be conducted in animal models to explore its potential for tissue regeneration. The compound would be administered locally or systemically. The effects on muscle regeneration and the generation of mononucleated cells would be assessed by histological analysis. All procedures must be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for myoseverin are not extensively reported in public sources. The compound is a small molecule and is typically stored as a powder at -20°C. For in vivo applications, it would be formulated in a suitable vehicle.
|
| Toxicity/Toxicokinetics |
Toxicological data for myoseverin are limited. The compound is for research use only and is not for human consumption. Its effects on the cytoskeleton could have broad implications. Comprehensive toxicology studies would be required for any future therapeutic application.
|
| References | |
| Additional Infomation |
Myoseverin is a research-grade chemical probe, and its primary application is in the study of cell fusion and muscle biology. Its unique ability to induce myotube fission makes it a valuable tool for investigating the mechanisms of cell fusion and for exploring potential applications in tissue engineering. The compound is not an approved drug and has not entered clinical trials. It is commercially available from various chemical suppliers for research purposes only.
|
| Molecular Formula |
C24H28N6O2
|
|---|---|
| Molecular Weight |
432.5181
|
| Exact Mass |
432.227
|
| Elemental Analysis |
C, 66.65; H, 6.53; N, 19.43; O, 7.40
|
| CAS # |
267402-71-1
|
| Related CAS # |
267402-71-1
|
| PubChem CID |
4273
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
661.3±65.0 °C at 760 mmHg
|
| Melting Point |
108 °C
|
| Flash Point |
353.7±34.3 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
3.04
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
32
|
| Complexity |
551
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N([H])C1=C2C(=NC(N([H])C([H])([H])C3C([H])=C([H])C(=C([H])C=3[H])OC([H])([H])[H])=N1)N(C([H])=N2)C([H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
IDCOTQWQVPRTNK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H28N6O2/c1-16(2)30-15-27-21-22(25-13-17-5-9-19(31-3)10-6-17)28-24(29-23(21)30)26-14-18-7-11-20(32-4)12-8-18/h5-12,15-16H,13-14H2,1-4H3,(H2,25,26,28,29)
|
| Chemical Name |
2-N,6-N-bis[(4-methoxyphenyl)methyl]-9-propan-2-ylpurine-2,6-diamine
|
| Synonyms |
Myoseverin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 87~250 mg/mL (201.2~578.0 mM)
Ethanol: ~22 mg/mL (~50.9 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (4.81 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (4.81 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3120 mL | 11.5602 mL | 23.1203 mL | |
| 5 mM | 0.4624 mL | 2.3120 mL | 4.6241 mL | |
| 10 mM | 0.2312 mL | 1.1560 mL | 2.3120 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
